Gland Pharma Limited IPO (Gland Pharma IPO) Detail

Add to Calendar 2020-11-09 12:00 AM 2020-11-11 12:00 AM Asia/Kolkata Gland Pharma Limited IPO (Gland Pharma IPO) Detail Gland Pharma Limited India

Hyderabad-based Gland Pharma Limited is coming up with the largest IPO in the pharmaceuticals space. The issue size of the IPO is Rs.6,500 cr which is a combination of a fresh issue of Rs.1,250 cr and an Offer for sale of Rs.5,230 cr. The IPO is all set to open on 9th November and will be closing on 11th November. 

Fosun Pharma is the holding company with a 74% stake which is expected to reduce to 58.3% post IPO. A number of other shareholders such as Gland Celsus, Empower Trust and Nilay Trust are also expected to reduce their stake via this IPO. Gland Pharma is one of the fastest growing generic injectables-focused company by revenue in the United States from 2014-2019. The B2B business model of the company makes it unique and enabled it to deliver strong revenue and Pat growth of 27.4% and 55.2% from 2018-2020. Operationally too, Gland Pharma is extremely efficient as it draws a margin of 39% on an average. The Company believes in using its internal cashflows to expand its business and for its working capital needs. Even after a decent capex each year, it has a sufficient cash balance. The Company has a distribution network spread over 60 countries including the US, Europe, China, Australia, India and RoW. Hence, as the business model and strategies followed by Gland Pharma are extremely sound, it is a good IPO to subscribe to at this point. Investors can also hold the stock from a longer term perspective as the valuations at a P/E of 30x are extremely favourable with no competitors in India. 

Gland Pharma has a robust business model wherein it partners with leading pharmaceutical companies with strong and independent sales and distribution networks for its products. Majority of its business is B2B but it also follows a B2C model when it comes to India where its products are primarily marketed and sold to institutions such as hospitals, long-term care facilities and clinics through stockists and distributors. Currently, Gland has seven manufacturing facilities in India comprising of four finished formulations facilities with a capacity of approximately 755 million units per annum and three USFDA approved API facilities. Moreover, it has 267 ANDA filings in the US of which 215 were already approved and 52 are in the pipeline of approval. Its key customers include Athenex Pharmaceutical Division, Sagent Pharmaceuticals, Inc. and Apotex Inc. 

Gland Pharma has done a tremendous job in terms of growth in its Top and Bottom-Line. The Company has delivered constant returns to its shareholders – ROE at an average of 18.1% and ROCE at 16.8% in the period 2018-20. The debt free nature of its business enables it to cushion through tough times and infact the company is looking for inorganic growth opportunities to strengthen its vertical integration. 

US Pricing pressure or Delay in USFDA approvals
High customer concentration risks with 40% of Gland’s revenues coming from its Top five clients
New entrants in pure formulations space can lead to Competition Risks
Future Acquisitions might pose as Synergy Risks going forward

Overall, Gland Pharma with its strong B2B model, high gross margins and better revenue visibility seems to be an attractive bet. Additionally, because of the ongoing pandemic pharma has been in focus since the past few months and it seems that the pharma cycle has turned for the better. Gland Pharma could be a strong contender in the pure formulations space.

Therefore, investors can subscribe to this IPO and hold the stock from a longer-term perspective.

Issue Detail

  • Issue Open: Nov 09, 2020
  • Issue Close: Nov 11, 2020
  • Issue Type: Book Built Issue IPO
  • Face Value: Rs. 1 per equity share
  • Price Band: Rs. 1490 to Rs. 1500 per equity share
  • Bid Lot:10 Shares
  • Minimum Order Quantity:10 Shares
  • Listing At: BSE, NSE
  • Issue Size: • Rs. 6,479.55 Cr

Current Bidding Status

Number of Times Subscribed (BSE + NSE)
As on Date & Time QIB NII RII Employee Others Total

Listing Day Trading Information

Issue Price - -
Open - -
Low - -
High - -
Last Trade - -
Volume - -

Gland Pharma Limited Red Herring Prospectus

Gland Pharma Limited User Rating


Gland Pharma Limited Life IPO Reviews

Gland Pharma Limited IPO News & Updates

Frequently Asked Questions

Yes, you can always trade an IPO through a discount broker. Buying & selling an IPO becomes very easy once the trading and the demat account are set up appropriately.
Following are the benefits in buying and selling an IPOs through a discount broker. Reduced Brokerage Fee: Discount brokers charge a flat brokerage which is missing in case of full service brokers. Full service brokers usually charge %age brokerage and this incurs a lot of cost to an investors. So if any full service broker charge a brokerage of let say 0.03% then on a purchase of shares of worth of Rs 200,000 you end up paying Rs 600+ Taxes. In our case we charge a flat brokerage of Rs 20 + Taxes. Discount brokers therefore saves a lot of money of investors. Better Trading Platform: Usually discounts brokers don’t provide a good trading platform and experience but there are few discounts brokers like Samco, who are now focussing on delivering a world class trading platform and top notch user experience. Therefore narrowing down the gap between discount brokers and full service brokers.
Technically Speaking, SEBI has made mandatory to buy an IPO through ASBA channel but there is no regulation on how any investor can sell an IPO allotted shares. Therefore, smart investors can always sell IPO allotted shares through a discount broker


Start IPO Trading through SAMCO

Don't have a Trading Account !!!
Open an account with Samco and Do IPO Trading for Just Rs 20. For more details, share your contact details with us